Key findings included 94% of test-phase responders experienced at least a 50% decrease in episodes of UUI.

Medtech companies are increasingly investing in neuromodulation to treat UUI, which is estimated to impact 20% of adults ...

Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, announced positive 12-month outcomes1 from its pivotal trial of the Neuspera SNM ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...

The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...

Barely a month after winning FDA clearance for its long-lasting implant to treat bladder dysfunction, Axonics is wasting no time in bringing the device to the masses. The Southern California-based ...

Sacral neuromodulation (SNM) is effective -- at least in the short term -- for patients with a type of urinary tract dysfunction, according to Swiss investigators. In a sham-controlled, double-blind ...

WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...